Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
anti-?2-glycoprotein-I antibody affinity. J Immunol 1998; 161: 2038—2043.
44. Vlachoyiannopoulos PG, Petrovas C, Tektonidou M, et al. Antibodies to 2-glycopro-tein-I: urea resistance binding specificity and association with thrombosis. J Clin Immunol 1999; 18: 380—391.
45. Molina JF, Gutierrez-Urena S, Molina J, et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 291—296.
46. Cucurul E, Gharavi AE, Diri E, et al. IgA anticardiolipin and anti-?2-glycoprptein-I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci 1999; 418: 55—60.
47. Samarkos M, Asherson RA, Loizou S. The clinical significance of IgA antiphospholipid antibodies. J Rheumatol 2001; 28; 694—697.
48. Bizzaro N, Pasini P, Finco B. False-positive reactions for IgA anti-phospholipid and anti- 2-glycoprotein-I antibodies in patients with IgA monoclonal gammapathy. Clin Chem 1999; 45: 2007—2010.
49. Hanly JG, Hong C, James H, Mansour M, Jones JV. Requirement of ?2-glycoprotein-I as cofactor in the binding for IgM and IgA anticardi-olipin antibodies. J Rheumatol 1995; 22: 1091— 1096.
50. Gharavi AE, Harris EN, Asherson RA, Hughes GR. Anticardiolipin antibodies: isotype distribution and phospholipid stecificity. Ann Rheum Dis 1987; 46: 1—6.
51. Selva-OCallaghan A, Ordi-Ros J, Monegal-Ferran F, et al. IgA anticardiolipin antibodies — relation with other antiphospholipid antibodies and clinical significance, Thromb Haemost 1998; 79: 282—285.
52. Weidmann CE, Wallace DJ, Peter JB, et al. IgG, IgM and IgA antiphospholipid antibody iso-types in systemic lupus erythematosus. J Rheumatol 1988; 15: 74—79.
53. Hamilton RG. Human IgG subclasss measurement in the clinical laboratory. Clin Chem 1987; 33: 1707—1725.
54. Gharavi AE, Harris EN, Lockshin MD, et al. IgG subclass and light chain distribution of anticardiolipinn and anti-DNA antibodies in sys-
SHS-OOO4.qxd 21.11.2006 16:56 Page 245
45
ГЛАВА 8. Клиническое значение антифосфолипидных антител
temic lupus erythematosus. Ann Rheum Dis 1988; 47: 286—290.
55. Tsutsumi A, Koike T, Ichikawa K, et al. IgG subclass distribution of anticardiolipin antibody in patients with systemic lupus erythematosus. J Rheumatology 1988; 15: 1764—1767.
56. Loizou S, Cofiner C, Weetman AP, Walport MJ. Immunoglobulin class and IgG subclass distribution of anticardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders. Clin Exp Immunol 1992; 90: 434— 439.
57. Samaritano LR, Ng S, Sobel R, et al. Anticardiolipin IgG subclass. Association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum 1997; 40: 1998—2006.
58. Samarkos M, Davies KA, Gordon C, et al. IgG subclass distribution of antibodies against ?2-GPI and cardiolipin in patients with systemic lupus erythematosus and primary antiphospho-lipid syndrome, and their clinical associations. Rheumatology 2001; 40: 1026—1032.
59. Arvieux J, Roussel B, Ponard D, Colomb MG. IgG2subclass resriction of anti-?2-glycopro-tein I antibodies in autoimmune patients. Clin Exp Immunol 1994; 95: 310—315.
60. Arveux J, Darnige L, Caron C, et al. Development of an ELISA for autoantibodies to pro-thrombin showing their orevalence in patients with lupus anticoagulant. Thromb Haemost 1995; 74: 1120—1125.
61. Galli M, Beretta G, Daldossi M, et al. Different anticoagulant and immunological properties anf anti-prothrombin antibodies in patients with antiphospholipid antibodies. 1997; 77: 486— 491.
62. Amengual O, Atsuni T, Koike T. Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis Rheum 2003; 48: 886—895.
63. Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance. Blood 1999; 93: 2149—2157.
64. Horbach D, van Oort E, Derksen R, de Groot P. The contribution of anti-prothrombin antibodies to lupus anticoagulant activity - discrimination between functional and non-functional anti-prothrombin-antibodies. Thromb Haemost 1998; 79: 790—5.
65. Akimoto T, Akama T, Kono I, Sumida T. Relationship between clinical feature and binding domains of anti-prothrombon autoantibodies in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 1999; 8: 761—766.
66. Nojima J, Kuratsune H, Suehisa E, et al. Association between the prevalence of antibodies to ?2-glycoprotein-I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus anr thrombotic and throm-bocytopenic complications. Clin Chem 2001; 47: 1008—1015.
67. Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and non-SLE disorders. Ann Intern Med 1990; 112: 682.
68. Abu-Shakra, M, Gladman, D, Urowitz, MB, Farewell, V. Anticardiolipin antibodies in systemic lupus erythematosus: Clinical and laboratory correlations. Am J Med 1995; 99: 624.
